**Editorials**

**Measuring Flares in Rheumatoid Arthritis. (Why) Do We Need Validated Criteria?**
A. van der Maas, A.A. den Broeder .................................. 189

Belimumab in Systemic Lupus Erythematosus — What Can Be Learned from Longterm Observational Studies?
A.A. Bengtsson ................................................................. 192

**Articles**

Updated Method Guidelines for Cochrane Musculoskeletal Group Systematic Reviews and Metaanalyses

Update of Strategies to Translate Evidence from Cochrane Musculoskeletal Group Systematic Reviews for Use by Various Audiences

Continued Benefit of Tocilizumab Plus DMARD Therapy in Patients with RA and Inadequate Clinical Responses by Week 8 of Treatment

Flares in RA: Frequency and Management. A Report from the BRASS Registry
V.P. Bykerk, N. Shadick, M. Frits, et al .............................. 227

Clinical, Functional, and Radiographic Implications of Time to Treatment Response in Patients with Early RA: a Posthoc Analysis of the PREMIER Study
E.C. Keystone, B. Haraoui, B. Guérette, N. Mozaftarian, S. Liu, A. Kavanaugh .................................................. 235

Tocilizumab in Adult-onset Still’s Disease: the Israeli Experience
O. Elkayam, N. Jines, Z. Dranitzki, et al .............................. 244

Inflammation and Disease Activity are Associated with High Circulating Cardiac Markers in RA Independently of Traditional Cardiovascular Risk Factors
J. Avouac, C. Meune, C. Chenevier-Gobeaux, et al .......................... 248

Health Literacy Predicts Discrepancies Between Traditional Written Patient Assessments and Verbally Administered Assessments in RA
J.M. Hirsh, L.A. Davis, I. Quinzanos, A. Keniston, L. Caplan ............................................... 256

Number of Ruptured Tendons and Surgical Delay as Prognostic Factors for the Surgical Repair of Extensor Tendon Ruptures in the Rheumatoid Wrist
Y. Sakuma, K. Ochi, T. Iwamoto, et al ........................................ 265

Antihomocitrullinated Fibrinogen Antibodies Are Specific to RA and Frequently Bind Citrullinated Proteins/peptides
M. Scinocca, D.A. Bell, M. Racapé, et al ........................................ 270

Serum Cytokine Profile of Unaffected First-degree Relatives of Patients with RA
L. Barra, K. Summers, D. Bell, E. Cairns ........................................ 280

Safety of Etanercept and MTX in Patients with RA and Hepatitis C Virus Infection: A Multicenter Randomized Clinical Trial
F. Iannone, G. La Montagna, G. Bagnato, E. Gremese, A.R. Giardina, G. Lapadula ........................................ 286

A Clinical, Pathological, and Genetic Characterization of MTX-associated Lymphoproliferative Disorders
N. Yamakawa, M. Fujimoto, D. Kawabata, et al ........................................ 293

Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with SLE
E.M. Ginzler, D.J. Wallace, J.T. Merrill, et al, and the LBSL02/99 Study Group ........................................ 300

Peripheral Arterial Disease in SLE: Prevalence and Risk Factors

Evidence for Genetic Association of CARD9 and SNAPC4 with Ankylosing Spondylitis in a Chinese Han Population
X. Ma, Y. Liu, H. Zhang, et al ........................................ 318

Comparison of Phenotype and Outcome in Microscopic Polyangiitis Between Europe and Japan
S. Furuta, A.N. Chaudhry, Y. Hamano, et al ........................................ 325

**Contents continued opposite inside back cover . . .**
Plasma Adipokine Levels and Their Association with Overall Burden of Painful Joints among Individuals with Hip and Knee OA
A.V. Perruccio, N.N. Mahomed, V. Chandran, R. Gandhi .......................... 334

Pediatric Rheumatology
A Longterm Prospective Real-life Experience with Leflunomide in JIA
The Relationship Between Physical Activity Levels and Pain in Children with JIA
E. Limenis, H.A. Grosbein, B.M. Feldman .......................... 345

Images in Rheumatology
Pannus Tissue Mimicking Enchondroma
T. Akalin, B. Goker, H. Selek .................................................. 352

OMERACT 11
11th International Consensus Conference on Outcome Measures in Rheumatology Pinehurst, North Carolina, USA – May 12-17, 2012

Imaging and Other Biomarkers
Selecting MRI Outcome Measures for JIA Clinical Trials: First Report of the MRI in JIA Special Interest Group
Methodologies for Semiquantitative Evaluation of Hip OA by MRI: Approaches Based on the Whole Organ and Focused on Active Lesions
Preliminary Validation of 2 MRI Scoring Systems for OA of the Hip According to the OMERACT Filter
Responsiveness in RA. A Report from the OMERACT 11 Ultrasound Workshop
A. Iagnocco, E. Naredo, R. Wakefield, et al .......................... 379
Update on the OMERACT MRI Task Force: Research and Future Directions
P.G. Conaghan, F.M. McQueen, P. Bird, et al ....................... 383
Iterative Development and Reliability of the OMERACT Hand OA MRI Scoring System
I.K. Haugen, M. Østergaard, I. Eshed, et al ......................... 386
The OMERACT-RAMRIS RA MRI Joint Space Narrowing Score: Intraobserver and Interobserver Reliability and Agreement with CT and Conventional Radiography
Determining a MRI Inflammatory Activity Acceptable State Without Subsequent Radiographic Progression in RA: Results from a Followup MRI Study of 254 Patients in Clinical Remission or Low Disease Activity

Letters
Immunoglobulin G Subclass Profile of Anticitrullinated Peptide Antibodies Specific for Epstein Barr Virus-derived and Histone-derived Citrullinated Peptides
Human Bartonella Infective Endocarditis is Associated with High Frequency of Antiproteinase 3 Antibodies
E. Aslangul, C. Goulvestre, Z. Mallat, J-L. Mainardi ............ 408